MEDI2228, an ADC that targets the extracellular domain of human BCMA, demonstrated clinical efficacy at all dose levels in treating patients with relapsed/refractory multiple myeloma.
Data from a preliminary phase 1b/2 study demonstrated a single low-dose infusion of ciltacabtagene autoleucel resulted in early, deep, and durable responses in heavily pretreated patients with multiple myeloma.